Results 51 to 60 of about 9,765 (234)

Addition of ribavirin to daclatasvir plus asunaprevir for chronic hepatitis C 1b patients with baseline NS5A resistance-associated variants improved response

Journal of the Formosan Medical Association, 2017
Daclatasvir is a nonstructural protein 5A inhibitor with potent activity against hepatitis C virus genotypes 1–6 in vitro, and asunaprevir is a nonstructural protein 3 protease inhibitor with activity against genotypes 1, 4, 5, and 6.
Chun-Ming Hong, Chun-Jen Liu, Shiou-Hwei Yeh, Pei-Jer Chen   +3 more
doaj   +1 more source

Polarization restricts hepatitis C virus entry into HepG2 hepatoma cells [PDF]

, 2009
The primary reservoir for hepatitis C virus (HCV) replication is believed to be hepatocytes, which are highly polarized with tight junctions (TJ) separating their basolateral and apical domains.
Balfe, Peter, Davis, Christopher, Farquhar, Michelle J, Harris, Helen J, McKeating, Jane A, Mee, Christopher J, Reynolds, Gary, van IJzendoorn, Sven C D, Wilson, Garrick   +8 more
core   +3 more sources

Fast Hepatitis C Virus RNA Elimination and NS5A Redistribution by NS5A Inhibitors Studied by a Multiplex Assay Approach [PDF]

Antimicrobial Agents and Chemotherapy, 2015
ABSTRACT While earlier therapeutic strategies for the treatment of hepatitis C virus (HCV) infection relied exclusively on interferon (IFN) and ribavirin (RBV), four direct-acting antiviral agents (DAAs) have now been approved, aiming for an interferon-free strategy with a short treatment duration and fewer side effects.
Dandan, Liu, Juan, Ji, Tanya P, Ndongwe, Eleftherios, Michailidis, Charles M, Rice, Robert, Ralston, Stefan G, Sarafianos   +6 more
openaire   +2 more sources

Features of resistance-associated substitutions after failure of multiple direct-acting antiviral regimens for hepatitis C

JHEP Reports, 2020
Background & Aims: We aimed to clarify the features of resistance-associated substitutions (RASs) after failure of multiple interferon (IFN)-free regimens in HCV genotype 1b infections.
Jun Itakura, Masayuki Kurosaki, Satoru Kakizaki, Keisuke Amano, Nobuaki Nakayama, Jun Inoue, Tetsu Endo, Hiroyuki Marusawa, Chitomi Hasebe, Kouji Joko, Shuichi Wada, Takehiro Akahane, Youhei Koushima, Chikara Ogawa, Tatsuya Kanto, Masashi Mizokami, Namiki Izumi   +16 more
doaj   +1 more source

Direct binding of a hepatitis C virus inhibitor to the viral capsid protein. [PDF]

PLoS ONE, 2012
Over 130 million people are infected chronically with hepatitis C virus (HCV), which, together with HBV, is the leading cause of liver disease. Novel small molecule inhibitors of Hepatitis C virus (HCV) are needed to complement or replace current ...
Smitha Kota, Virginia Takahashi, Feng Ni, John K Snyder, A Donny Strosberg   +4 more
doaj   +1 more source

Discovery of Potent Hepatitis C Virus NS5A Inhibitors with Dimeric Structures [PDF]

Antimicrobial Agents and Chemotherapy, 2011
ABSTRACTThe exceptionalin vitropotency of the hepatitis C virus (HCV) NS5A inhibitor BMS-790052 has translated into anin vivoeffect in proof-of-concept clinical trials. Although the 50% effective concentration (EC50) of the initial lead, the thiazolidinone BMS-824, was ∼10 nM in the replicon assay, it underwent transformation to other inhibitory ...
Julie A, Lemm, John E, Leet, Donald R, O'Boyle, Jeffrey L, Romine, Xiaohua Stella, Huang, Daniel R, Schroeder, Jeffrey, Alberts, Joseph L, Cantone, Jin-Hua, Sun, Peter T, Nower, Scott W, Martin, Michael H, Serrano-Wu, Nicholas A, Meanwell, Lawrence B, Snyder, Min, Gao   +14 more
openaire   +2 more sources

Retreatment of Direct Acting Agents (DAAs) After Initial DAA Failure in Hepatitis C Patients

Hepatology Research, EarlyView.
ABSTRACT Background and Aims Glecaprevir/pibrentasvir (GLE/PIB) and sofosbuvir/ledipasvir (SOF/LDV) are widely used as first‐line direct‐acting antiviral (DAA) regimens for chronic hepatitis C, achieving high virus eradication rates. However, a small proportion of patients experience treatment failure, and the optimal retreatment strategies for such ...
Nobuharu Tamaki, Masayuki Kurosaki, Hironori Ochi, Hideki Fujii, Yuichiro Suzuki, Takuya Sho, Hayato Hikita, Hiroyuki Marusawa, Yasuhiro Asahina, Namiki Izumi, Tatsuya Kanto   +10 more
wiley   +1 more source

Hepatitis C Drugs: The End of the Pegylated Interferon Era and the Emergence of All-Oral, Interferon-Free Antiviral Regimens: A Concise Review

Canadian Journal of Gastroenterology and Hepatology, 2014
Between 2001 and 2011, the standard of care for chronic hepatitis C virus (HCV) infection was a combination of pegylated interferon (PEGIFN) and ribavirin (RBV).
Alan Hoi Lun Yau, Eric M Yoshida
doaj   +1 more source

Era of direct acting anti-viral agents for the treatment of hepatitis C. [PDF]

, 2018
Hepatitis C infection is universal and the most common indication of liver transplantation in the United States. The period of less effective interferon therapy with intolerable side effects has gone.
Ahmed, Monjur
core   +1 more source

Requirement for chloride channel function during the hepatitis C virus life cycle [PDF]

, 2015
Hepatocytes express an array of plasma membrane and intracellular ion channels, yet their role during the hepatitis C virus (HCV) life cycle remains largely undefined.
Harris, M, Igloi, Z, Lippiat, JD, Mankouri, J, Mohl, BP   +4 more
core   +1 more source